Premier Biotech

Premier Biotech provides oral fluid drug testing from end to end. It manufactures the FDA-cleared Oral-Eze collection device, performs the screening and confirmation testing in its own high-complexity laboratory in Minneapolis, and delivers results through a proprietary software portal. The business serves corporate employers, government agencies, addiction treatment clinics, and criminal justice programs.

The firm is a long-time laboratory partner to the Alltyr clinic in St. Paul, founded by the late Dr. Mark Willenbring, a former director at the National Institute on Alcohol Abuse and Alcoholism. Premier Biotech provides quantitative urine drug monitoring to support medication adherence and relapse detection in patients receiving treatment for opioid and alcohol use disorders.

Yes. The Oral-Eze device is marketed to third-party laboratories, occupational health providers, and research organizations that want to perform oral fluid testing without developing their own hardware. This creates a parallel revenue stream where Premier Biotech earns device sales and licensing fees from facilities that compete with its own lab services.

Oral fluid collection can be observed without the privacy requirements of urine collection, significantly reducing the opportunity for sample adulteration or substitution. The detection window is shorter, typically reflecting use within the prior 24 to 48 hours, which makes it valuable for post-accident and reasonable-suspicion scenarios where recent use is the relevant question.

Federal workplace testing operates under Substance Abuse and Mental Health Services Administration authority and does not recognize state-level legalization as a defense for a positive test. Premier Biotech's oral fluid panels include tetrahydrocannabinol for federally regulated programs, though the company also serves private employers who may configure panels to reflect their own drug-free workplace policies.

Premier Biotech is privately held, and ownership details are not publicly recorded. The business has avoided outside capital announcements, suggesting it is operator-owned and sustained through laboratory and device revenues rather than venture or private equity backing.

The Minneapolis laboratory operates as a high-complexity testing facility under the Clinical Laboratory Improvement Amendments, holding CLIA certification and state-level licensure. It participates in proficiency testing programs required for regulated workplace drug testing and for clinical toxicology reporting to healthcare providers.